Focal treatment strategy for Prostate Cancer (PCa) is playing a growing role in today’s surgical practice. By combining the latest imaging and treatment technologies, Focal One® brings the answer to current requirements for ideal focal therapy: accurate and MR-fused imaging, non-invasive approach, precise and efficient therapeutic HIFU energy and treatment validation imaging with post-treatment MRI.
Focal One® is indicated for the treatment of localized prostate cancer. Focal One® is intended for the destruction by rectal high-intensity focused ultrasound of a localized adenocarcinoma of the prostate. Manufactured by EDAP TMS, Focal One® is a regulated medical device that carries the CE marking under this regulation. Class IIb, its conformity assessment was performed by G-MED (0459). It is advisable to consult the user manual beforehand.